BioHarvest Sciences Inc. (CNVCF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CNVCF, $ (piyasa değeri 0) fiyatla Healthcare işi olan BioHarvest Sciences Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 66/100 puan alıyor.
Son analiz: 16 Mar 2026BioHarvest Sciences Inc. (CNVCF) Sağlık ve Boru Hattı Genel Bakışı
BioHarvest Sciences Inc. operates in the nutraceutical and cannabis sectors, leveraging its proprietary plant cell growth technology to produce and market Vinia, a red grape powder nutraceutical, and medical cannabis. With a focus on international markets, the company aims to deliver plant-based solutions without traditional agricultural methods.
Yatırım Tezi
BioHarvest Sciences Inc. presents a speculative investment opportunity in the nutraceutical and cannabis sectors, driven by its innovative Bioplant technology. The company's potential lies in its ability to efficiently produce plant-based compounds, offering a sustainable alternative to traditional agriculture. Key value drivers include the growth of Vinia sales, expansion into new markets, and the development of novel cannabis-based products. The company's negative P/E ratio of -17.80 and a negative profit margin of -40.9% indicate it is not yet profitable. A beta of 1.49 suggests higher volatility than the market. Upcoming catalysts include potential regulatory approvals for its cannabis products and expansion of its distribution network. However, investors should be aware of the risks associated with operating in the highly regulated cannabis industry and the challenges of scaling production and marketing efforts.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.11B reflects its position as a smaller player in the nutraceutical and cannabis markets.
- Negative P/E Ratio of -17.80 indicates the company is currently not profitable, requiring careful monitoring of its path to profitability.
- Gross Margin of 56.7% suggests strong pricing power and efficient production of its Vinia product.
- Beta of 1.49 indicates higher volatility compared to the overall market, which may appeal to risk-tolerant investors.
- No Dividend Yield reflects the company's focus on reinvesting earnings for growth rather than returning capital to shareholders.
Rakipler & Benzerleri
Güçlü Yönler
- Proprietary Bioplant technology.
- Established Vinia brand.
- Expertise in cannabis cultivation.
- International operations.
Zayıflıklar
- Limited product portfolio.
- Negative profitability.
- Small market capitalization.
- Reliance on regulatory approvals.
Katalizörler
- Upcoming: Potential regulatory approvals for cannabis products in new markets.
- Ongoing: Expansion of Vinia distribution network through strategic partnerships.
- Ongoing: Development of new cannabis-based products with unique cannabinoid profiles.
- Ongoing: Continued innovation in Bioplant technology to improve efficiency and scalability.
Riskler
- Potential: Competition from established players in the nutraceutical and cannabis industries.
- Potential: Regulatory changes impacting the cannabis market.
- Potential: Fluctuations in cannabis prices affecting profitability.
- Ongoing: Challenges in scaling production and marketing efforts.
- Ongoing: Dependence on regulatory approvals for cannabis products.
Büyüme Fırsatları
- Expansion of Vinia Sales: BioHarvest Sciences can increase Vinia sales through targeted marketing campaigns and expansion into new geographic markets. The global nutraceutical market is estimated to reach $441.7 billion by 2026, offering a substantial opportunity for growth. By focusing on e-commerce channels and strategic partnerships with retailers, the company can reach a wider customer base and drive revenue growth. Timeline: Ongoing.
- Development of Novel Cannabis Products: The company can leverage its Bioplant technology to develop novel cannabis-based products with unique cannabinoid profiles. The global medical cannabis market is projected to reach $55.8 billion by 2026. By focusing on research and development, BioHarvest Sciences can create differentiated products that address specific medical needs and capture a share of this growing market. Timeline: Ongoing.
- Strategic Partnerships: Forming strategic partnerships with established players in the nutraceutical and cannabis industries can accelerate growth and expand market reach. By partnering with distributors, retailers, and research institutions, BioHarvest Sciences can leverage their expertise and resources to commercialize its products more effectively. Timeline: Ongoing.
- Regulatory Approvals: Obtaining regulatory approvals for its cannabis products in key markets can unlock significant growth opportunities. As more countries and regions legalize medical and recreational cannabis, BioHarvest Sciences can capitalize on these opportunities by securing the necessary licenses and permits to operate in these markets. Timeline: Upcoming.
- Technological Innovation: Continued investment in research and development to further enhance its Bioplant technology can create a sustainable competitive advantage. By improving the efficiency and scalability of its production process, BioHarvest Sciences can reduce costs, increase yields, and develop new plant-based products. Timeline: Ongoing.
Fırsatlar
- Expansion into new geographic markets.
- Development of novel cannabis products.
- Strategic partnerships.
- Increasing legalization of cannabis.
Tehditler
- Competition from established players.
- Regulatory changes.
- Fluctuations in cannabis prices.
- Economic downturn.
Rekabet Avantajları
- Proprietary Bioplant technology for efficient plant cell growth.
- Patents protecting its technology and products.
- Established brand recognition for Vinia in the nutraceutical market.
- Expertise in cannabis cultivation and extraction.
CNVCF Hakkında
BioHarvest Sciences Inc. is a biotechnology company focused on developing and commercializing plant-based products using its proprietary plant cell growth (Bioplant) technology. Founded with the vision of producing high-value plant-based compounds sustainably and efficiently, the company has evolved into a player in both the nutraceutical and cannabis industries. Its core technology allows for the production of active secondary metabolites without the need to grow the entire plant, offering a more controlled and environmentally friendly approach. The company's flagship product, Vinia, is a red grape powder nutraceutical marketed for its antioxidant properties and potential cardiovascular benefits. Vinia is designed to deliver the health benefits of red wine without the alcohol or sugar. In addition to Vinia, BioHarvest Sciences is involved in the development and production of medical cannabis, leveraging its Bioplant technology to cultivate cannabis cells and extract valuable cannabinoids. The company operates internationally, with a focus on markets where nutraceuticals and medical cannabis are legal and regulated. BioHarvest Sciences is based in Vancouver, Canada, and has operations in Israel, where much of its research and development takes place. The company aims to expand its product portfolio and market reach through continued innovation and strategic partnerships.
Ne Yaparlar
- Develops plant cell growth technology to produce active compounds.
- Manufactures and markets Vinia, a red grape powder nutraceutical.
- Cultivates cannabis cells for medical cannabis production.
- Offers plant-based solutions without traditional agriculture.
- Focuses on nutraceutical and cannabis verticals.
- Operates internationally, including Israel and Canada.
İş Modeli
- Produces plant-based compounds using proprietary Bioplant technology.
- Sells Vinia directly to consumers and through retailers.
- Develops and commercializes medical cannabis products.
- Generates revenue through product sales and licensing agreements.
Sektör Bağlamı
BioHarvest Sciences Inc. operates within the rapidly evolving nutraceutical and cannabis industries. The nutraceutical market is driven by increasing consumer interest in health and wellness, with a global market size estimated to reach hundreds of billions of dollars. The cannabis industry is experiencing significant growth due to increasing legalization and acceptance of medical and recreational cannabis. BioHarvest Sciences competes with other nutraceutical companies and cannabis producers, including ADOIF (Advanz Pharma Corp), AMEUF (Amneal Pharmaceuticals Inc), COPHF (CorpHQ Inc), CSAMF (Cascadia Acquisition Corp), and EOFBY (Evolus Inc). The company's Bioplant technology offers a potential competitive advantage by providing a more sustainable and efficient production method.
Kilit Müşteriler
- Health-conscious consumers seeking natural supplements.
- Patients using medical cannabis for therapeutic purposes.
- Retailers and distributors of nutraceutical and cannabis products.
- Pharmaceutical companies interested in plant-based ingredients.
Finansallar
Grafik & Bilgi
BioHarvest Sciences Inc. (CNVCF) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Stocks That Hit 52-Week Lows Of Monday
· 12 Ağu 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· 7 Ağu 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
CNVCF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
CNVCF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, CNVCF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Ilan Sobel
CEO
Ilan Sobel brings extensive experience in the pharmaceutical and consumer goods industries to his role as CEO of BioHarvest Sciences Inc. His career spans various leadership positions, including roles in marketing, sales, and business development. He has a proven track record of driving growth and innovation in both established companies and startups. Sobel's background includes a strong focus on strategic planning, market analysis, and product commercialization. He is known for his ability to build high-performing teams and execute complex projects.
Sicil: Under Ilan Sobel's leadership, BioHarvest Sciences has focused on expanding its Vinia product line and advancing its cannabis program. Key achievements include securing partnerships for distribution and increasing brand awareness. Sobel has overseen the company's efforts to optimize its Bioplant technology and develop new applications for its platform. He has also guided the company through regulatory challenges and market fluctuations.
CNVCF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of over-the-counter (OTC) stocks. Companies in this tier often have limited financial disclosure and may not meet minimum listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significant risks due to the potential for lack of transparency and regulatory oversight. These companies may not be required to file regular reports with the SEC, making it difficult for investors to assess their financial health and business prospects. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure due to OTC listing.
- Lower liquidity and higher price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with the OTC market.
- Consult with a financial advisor.
- Check for any regulatory actions or legal disputes.
- Established Vinia brand in the nutraceutical market.
- Proprietary Bioplant technology.
- International operations.
- Experienced management team.
CNVCF Hakkında Sıkça Sorulan Sorular
CNVCF için değerlendirilmesi gereken temel faktörler nelerdir?
BioHarvest Sciences Inc. (CNVCF) şu anda yapay zeka skoru 66/100, orta puanı gösteriyor. Temel güçlü yan: Proprietary Bioplant technology.. İzlenmesi gereken birincil risk: Potential: Competition from established players in the nutraceutical and cannabis industries.. Bu bir finansal tavsiye değildir.
CNVCF MoonshotScore'u nedir?
CNVCF şu anda MoonshotScore'da 66/100 (Derece B) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
CNVCF verileri ne sıklıkla güncellenir?
CNVCF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler CNVCF hakkında ne diyor?
CNVCF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
CNVCF'a yatırım yapmanın riskleri nelerdir?
CNVCF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established players in the nutraceutical and cannabis industries.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
CNVCF'ın P/E oranı nedir?
CNVCF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için CNVCF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
CNVCF aşırı değerli mi, yoksa düşük değerli mi?
BioHarvest Sciences Inc. (CNVCF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
CNVCF'ın temettü verimi nedir?
BioHarvest Sciences Inc. (CNVCF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data as of 2026-03-16.
- AI analysis is pending for CNVCF, which may provide additional insights.